Arkolith/Insider Trading/VNDA/Form 4

Birznieks Gunther

SVP, Business DevelopmentVanda Pharmaceuticals Inc. (VNDA) · full profile →Form 4 · filed Mar 6, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$73K
Net Open-Market Flow
-$73K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 5, 2024Sell(S)9K$4.13$36K314K
Mar 4, 2024Sell(S)9K$4.30$38K322K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-027249) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML